Management of Peyronie's Disease after Collagenase (Xiaflex:^®)

Title:Management of Peyronie's Disease after Collagenase (Xiaflex:^®)

Volume: 16 Issue: 5

Author(s): Amjad Alwaal, Ahmed Aly Hussein, Uwais B. Zaid and Tom F. Lue

Affiliation:

Keywords: Pharmacotherapy, Peyronie’s disease, shock wave therapy, stem cell therapy, collagenase.

Abstract: Although the prevalence of Peyronie’s disease (PD) is reported to be 3-9% in men, the true prevalence is likely higher due to under-reporting. Many treatment modalities have been described for PD with varying degrees of success. In this article, we review and summarize the current literature pertaining to all pharmacotherapies (oral, intralesional, iontophoresis, and topical) and minimally invasive treatments available for PD (vacuum, traction device, shock wave therapy, and radiation treatment). Additionally, we discuss emerging therapies for PD that are still in pre-clinical development, including stem cell therapy.

Cite this article as:

Alwaal Amjad, Aly Hussein Ahmed, Zaid Uwais B. and F. Lue Tom, Management of Peyronie's Disease after Collagenase (Xiaflex:^®), Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450115666141114163128